Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors (Oncotarget (2019) 10 (5755-5767) DOI: 10.18632/oncotarget.27206)

Amanda M. Smith, Christine R.C. Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink, Andrew S. Moore

Research output: Contribution to journalComment/debate


This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below. Original article: Oncotarget. 2019; 10:5755-5767. Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3. 1The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia. 2Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia. 3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia. 4Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America. 5Current address: Garvan Institute of Medical Research, Darlinghurst, Australia. 6Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia. *These authors contributed equally to this work.

Original languageEnglish
Pages (from-to)305
Number of pages1
Issue number3
StatePublished - Jan 21 2020


Dive into the research topics of 'Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors (Oncotarget (2019) 10 (5755-5767) DOI: 10.18632/oncotarget.27206)'. Together they form a unique fingerprint.

Cite this